Publications by authors named "Maria Mar Martin Rodriguez"
Article Synopsis
- A study examined the persistence of adalimumab biosimilars compared to the original drug, analyzing data from 104 patients grouped by the type of medication received.
- Results showed that the biosimilars had higher persistence rates after 12 months, with no significant differences in mild adverse events across groups, but a higher occurrence of severe events in those who switched from the original to the biosimilar.
- Overall, biosimilars proved to be a cost-effective and clinically equivalent option for treating inflammatory bowel disease (IBD), without negatively impacting patient outcomes, supporting their use in healthcare sustainability.
